Table 1.
IDH mutation prevalence and prognostic implication across various solid malignancies.
| Disease | Gene | Mutation | Prevalence | Prognostic Implication |
|---|---|---|---|---|
| LGG/secondary GB | IDH1 | IDH1 R132 | >80% | Positive |
| iCCA | IDH1 | IDH1 R132 | 20% | Unclear |
| Chondrosarcoma | IDH1, IDH2 | IDH1 R132 IDH2 R172 |
50–60% | Positive (both) |
| Enchondroma | IDH1, IDH2 | IDH1-R132C/H, IDH2-R172S | 50% | Unclear |
| SNUCs | IDH1 | IDH2-R172S/T | 49% | Positive |
LGG: low-grade glioma; GB: glioblastoma; iCCA: intrahepatic cholangiocarcinoma; SNUCs: sinonasal undifferentiated carcinomas.